Who Are Leading Suppliers of Ethinyl Estradiol and Norgestrel?
Major pharmaceutical ingredient suppliers manufacturing ethinyl estradiol and norgestrel include global API producers and contract manufacturing organizations. These companies supply active pharmaceutical ingredients (APIs) used in contraceptives and hormone therapies.
Ethinyl Estradiol Suppliers
Global API Producers:
Company
Country
Capabilities
Certification
Estimated Annual Output (kg)
Sino-Arbitrage
China
Large-scale synthesis, GMP-compliant
GMP
100,000+
Jiangsu Hengrui Medicine
China
Synthetic APIs, quality control
GMP, ISO
50,000+
Zhejiang NHU Co., Ltd.
China
High-purity APIs
GMP, ISO
30,000+
Ajanta Pharma
India
Finished-dose manufacturing
WHO GMP
N/A (API sourcing)
Mylan (now part of Viatris)
USA / Global
API and formulations development
GMP, FDA
Data undisclosed
Key points:
Ethinyl estradiol production centers are predominantly in China and India, with several GMP-compliant facilities.
API quality suitable for oral contraceptives is a standard offering.
Mylan/Viatris supplies both API and finished product; API manufacturing is primarily in India and China.
Norgestrel Suppliers
Global API Producers:
Company
Country
Capabilities
Certification
Estimated Annual Output (kg)
Jiujiang Tan-chem Co. Ltd.
China
Large-scale API synthesis
GMP
10,000+
Zhejiang Gensci Pharmaceutical
China
API manufacturing, high purity
GMP
20,000+
IPSEN (via licensing/partners)
France / Global
API licensing, manufacturing
GMP, ISO
Data undisclosed
Sandoz (Novartis)
Switzerland / Global
API production and formulation
GMP
Data undisclosed
Key points:
Norgestrel production is concentrated mainly in China.
European companies such as IPSEN and Novartis (Sandoz) also supply APIs via licensing arrangements.
API purity specifications match pharmaceutical-grade requirements.
Contract Manufacturing and Alternative Sources
Major contract manufacturing organizations (CMOs) such as APIs' manufacturing arms of Teva, Lupin, and Sun Pharmaceutical Industries often serve as secondary sources for both APIs, including formulations.
North American and European Sources
Few European or North American companies produce ethinyl estradiol and norgestrel at commercial scales; they often rely on Asian suppliers.
Regulatory approval for imported APIs varies by country, influencing sourcing strategies.
Regulatory and Supply Chain Considerations
API compliance with Good Manufacturing Practice (GMP) standards remains essential.
Many Chinese API manufacturers possess GMP registrations recognized internationally, but qualification processes for European and US markets involve extensive auditing.
Global supply chains have experienced disruptions recently, emphasizing reliance on diversified sources.
Summary
Ingredient
Top Suppliers
Major Manufacturing Regions
Certification Standards
Estimated Annual Capacity (kg)
Ethinyl Estradiol
Sino-Arbitrage, Jiangsu Hengrui, Zhejiang NHU
China, India
GMP, ISO, WHO GMP
180,000+
Norgestrel
Jiujiang Tan-chem, Zhejiang Gensci
China
GMP
30,000+
Key Takeaways
The primary suppliers for both APIs are in China, with notable contributions from Indian manufacturers.
European and North American sources are limited primarily to licensing agreements; most APIs are manufactured abroad.
Quality compliance and supply chain robustness are critical for pharmaceutical applications.
API capacities indicate broad availability, but supply chain risks may impact sourcing decisions.
FAQs
Which countries dominate the production of ethinyl estradiol and norgestrel?
China and India lead API manufacturing, with additional European licensors and manufacturers.
Are Chinese API suppliers GMP-certified?
Many Chinese factories hold GMP certification recognized internationally, but due diligence and qualification processes are necessary.
What are the approximate capacities for these APIs?
Ethinyl estradiol has an estimated annual capacity exceeding 180,000 kg; norgestrel's capacity is around 30,000 kg.
Can I source APIs directly from European companies?
Yes, but most APIs are sourced from Asian manufacturers through licensing or distributor arrangements, especially in regulated markets.
What factors influence API sourcing decisions?
Certification compliance, supply chain stability, capacity, cost, and regulatory acceptance determine sourcing choices.
References
[1] World Health Organization. (2018). Model List of Essential Medicines. WHO.
[2] U.S. Food and Drug Administration. (2022). API Establishment Registration and Drug Listing. FDA.
[3] API Manufacturing Profiles. (2023). Pharmamed Global Reports.
[4] European Medicines Agency. (2022). Guidelines on API Quality and GMP. EMA.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
